From Nasdaq Group:

In the new bull market, many investors have disregarded value stocks for high-growth options. However, history shows that value stocks generally outperform growth stocks over the long term. Some value stocks, such as Alibaba Group, are currently undervalued and have strong potential to outperform by 2030. With a forward earnings multiple of 8.3x, Alibaba is considered a value stock, despite being a tech giant in e-commerce, cloud services, and AI. The company’s current challenges are linked to the slow Chinese economy, but analysts remain optimistic about its future growth prospects and the potential impact of AI on its cloud platform.
Another undervalued stock with strong potential is Enterprise Products Partners, a midstream energy provider with a low forward earnings multiple of 10.6x and a distribution yield of more than 7.1%. The company is well-positioned to benefit from increased demand for its pipelines and midstream assets, especially if an oil supply shortage materializes. Regardless of commodity price fluctuations, Enterprise has a history of generating high returns on invested capital. These factors make it a promising value stock for the coming years.
Pfizer, a pharmaceutical giant, also falls into the undervalued category with a dividend yield of over 5.9%. Despite challenges like declining COVID-19 sales and upcoming patent expirations for key products, Pfizer has a strong pipeline of new drugs and indications that are expected to drive significant revenue by 2030. The company also anticipates generating $25 billion in annual revenue by 2030 through business development deals. While Pfizer may face short-term headwinds, its long-term growth potential makes it an attractive investment option.



Read more at Nasdaq Group: Prediction: These Could Be the Best-Performing Value Stocks Through 2030